Anything less than $71 per share from J&J should not be accepted, in our view. |
Elliott is extremely disappointed in your decision to accept a revised Johnson & Johnson offer that clearly fails to maximize shareholder value, and is appalled at the board's failure to stand up for the shareholders you are charged to represent. |
We ask that you declare any subsequent offer with improved terms from Boston Scientific as superior. |